???global.info.a_carregar???
Paulo Lucio. Concluiu o(a) Doutoramento em Medicina em 1995 pelo(a) Universidade Nova de Lisboa Faculdade de Ciências Médicas e Doutoramento em Ciências da Saúde em 2002 pelo(a) Universidade Nova de Lisboa Faculdade de Ciências Médicas. É Director da Unidade de Hemato-Oncologia no(a) Fundação Champalimaud.
Identificação

Identificação pessoal

Nome completo
Paulo Jorge Monteiro da Silva Lucio

Nomes de citação

  • Lucio, Paulo

Identificadores de autor

Ciência ID
EF18-D355-BA74
ORCID iD
0000-0003-0175-7534

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Inglês Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador independente (B1)
Formação
Grau Classificação
2002
Concluído
 Ciências da Saúde (Doutoramento)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
"Detecção Imunológica de Doença Mínima Residual em Leucemias Linfoblásticas Agudas" (TESE/DISSERTAÇÃO)
 Muito Bom, por unanimidade, com Distinção e Louvor
1995
Concluído
 Hematologia Clinica (Título de especialista)
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
 19
1985
Concluído
 Medicina (Licenciatura)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
 16 valores
Percurso profissional

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
2014/01/15 - Atual Director da Unidade de Hemato-Oncologia Fundação Champalimaud, Portugal
2011/01/01 - 2015/02/28 Director do Laboratório de Hemato-Oncologia Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
2000/01/01 - 2011/12/31 Responsável pelo Laboratório de Citometria de Fluxo Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
2005/08/01 - 2006/12/31 Director da Unidade de Citometria de Fluxo Instituto de Medicina Molecular João Lobo Antunes, Portugal
2001/04/01 - 2006/04/15 Consultor de Hematologia Hospital de Santa Cruz, Portugal
2004/01/01 - 2005/07/31 Consultor da Unidade de Citometria de Fluxo Instituto de Medicina Molecular João Lobo Antunes, Portugal
1995/01/01 - 2002/12/31 Assistente Hospitalar de Hematologia Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
2001/04/30 - 2001/06/30 Chefe da Clinica Médica Hospital das Forças Armadas, Portugal
1999/01/01 - 2001/04/30 Chefe do Serviço de Hematologia e Imunohemoterapia Hospital das Forças Armadas, Portugal
1989/01/01 - 1995/07/31 Interno Complementar de Hematologia Clínica Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
Produções

Publicações

Artigo em revista
  1. Weisel, Katja; Dimopoulos, Meletios; Moreau, Philippe; Yagci, Munci; Larocca, Alessandra; Kanate, Abraham S.; Vural, Filiz; et al. "Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma". Leukemia & Lymphoma (2020): 1-10. http://dx.doi.org/10.1080/10428194.2020.1747066.
    10.1080/10428194.2020.1747066
  2. Mateos, Maria-Victoria; Cavo, Michele; Blade, Joan; Dimopoulos, Meletios A; Suzuki, Kenshi; Jakubowiak, Andrzej; Knop, Stefan; et al. "Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial". The Lancet 395 10218 (2020): 132-141. http://dx.doi.org/10.1016/s0140-6736(19)32956-3.
    10.1016/s0140-6736(19)32956-3
  3. Moreau, Philippe; Sonneveld, Pieter; Boccadoro, Mario; Cook, Gordon; Mateos, Ma Victoria; Nahi, Hareth; Goldschmidt, Hartmut; et al. "Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network". Haematologica 104 12 (2019): 2358-2360. http://dx.doi.org/10.3324/haematol.2019.224204.
    10.3324/haematol.2019.224204
  4. João, Cristina; Bergantim, Rui; Neves, Manuel; Chacim, Sérgio; Afonso, Celina; Barradas, João; Bernardo, Manuela; et al. "Multiple myeloma in elderly patients—a Portuguese multicentric real-life study". Annals of Hematology 98 7 (2019): 1689-1701. http://dx.doi.org/10.1007/s00277-019-03640-y.
    10.1007/s00277-019-03640-y
  5. Mateos, María-Victoria; Dimopoulos, Meletios A.; Cavo, Michele; Suzuki, Kenshi; Jakubowiak, Andrzej; Knop, Stefan; Doyen, Chantal; et al. "Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma". New England Journal of Medicine 378 6 (2018): 518-528. http://dx.doi.org/10.1056/nejmoa1714678.
    10.1056/nejmoa1714678
  6. João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; Esteves S; Esteves GV. "Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.". (2016): http://europepmc.org/abstract/med/27068406.
    10.1007/s00277-016-2662-6
  7. Kalina T; Flores-Montero J; Lecrevisse Q; Pedreira CE; van der Velden VH; Novakova M; Mejstrikova E; et al. "Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds.". (2015): http://europepmc.org/abstract/med/25345353.
    10.1002/cyto.a.22581
  8. João C; Coelho I; Costa C; Esteves S; Lucio P. "Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center.". (2015): http://europepmc.org/abstract/med/25038919.
    10.1007/s00277-014-2164-3
  9. Martins LR; Perera Y; Lúcio P; Silva MG; Perea SE; Barata JT. "Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.". (2014): http://europepmc.org/abstract/med/24473900.
  10. Parreira J; Lúcio P; João C; Macedo A; Sarmento AB; Geraldes C; Gonçalves C; Esteves G. "[Monoclonal gammopathies of indetermined significance: diagnosis and clinical follow-up guidelines].". (2014): http://europepmc.org/abstract/med/25409226.
  11. Martins LR; Lúcio P; Melão A; Antunes I; Cardoso BA; Stansfield R; Bertilaccio MT; et al. "Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.". (2013): http://europepmc.org/abstract/med/23925046.
    10.1038/leu.2013.232
  12. Dekking EH; van der Velden VH; Varro R; Wai H; Böttcher S; Kneba M; Sonneveld E; et al. "Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia.". (2012): http://europepmc.org/abstract/med/22948489.
    10.1038/leu.2012.125
  13. van Dongen JJ; Lhermitte L; Böttcher S; Almeida J; van der Velden VH; Flores-Montero J; Rawstron A; et al. "EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.". (2012): http://europepmc.org/abstract/med/22552007.
    10.1038/leu.2012.120
  14. Martins LR; Lúcio P; Silva MC; Gameiro P; Silva MG; Barata JT. "On CK2 regulation of chronic lymphocytic leukemia cell viability.". (2011): http://europepmc.org/abstract/med/21750986.
    10.1007/s11010-011-0947-6
  15. Martins LR; Lúcio P; Silva MC; Anderes KL; Gameiro P; Silva MG; Barata JT. "Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.". (2010): http://europepmc.org/abstract/med/20660292.
    10.1182/blood-2010-04-277947
  16. Dekking E; van der Velden VH; Böttcher S; Brüggemann M; Sonneveld E; Koning-Goedheer A; Boeckx N; et al. "Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay.". (2010): http://europepmc.org/abstract/med/21123134.
    10.1016/j.beha.2010.09.010
  17. Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; et al. "[Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].". (2010): http://europepmc.org/abstract/med/21627880.
  18. Weerkamp F; Dekking E; Ng YY; van der Velden VH; Wai H; Böttcher S; Brüggemann M; et al. "Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients.". (2009): http://europepmc.org/abstract/med/19387467.
    10.1038/leu.2009.93
  19. Neves H; Weerkamp F; Gomes AC; Naber BA; Gameiro P; Becker JD; Lúcio P; et al. "Effects of Delta1 and Jagged1 on early human hematopoiesis: correlation with expression of notch signaling-related genes in CD34+ cells.". (2006): http://europepmc.org/abstract/med/16410393.
    10.1634/stemcells.2005-0207
  20. Bueno C; Almeida J; Lucio P; Marco J; Garcia R; de Pablos JM; Parreira A; et al. "Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies.". (2004): http://europepmc.org/abstract/med/14754607.
  21. Vidriales MB; Pérez JJ; López-Berges MC; Gutiérrez N; Ciudad J; Lucio P; Vazquez L; et al. "Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.". (2003): http://europepmc.org/abstract/med/12586618.
    10.1182/blood-2002-08-2613
  22. Lucio P; Gaipa G; van Lochem EG; van Wering ER; Porwit-MacDonald A; Faria T; Bjorklund E; et al. "BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation.". (2001): http://europepmc.org/abstract/med/11480560.
    10.1038/sj.leu.2402150
  23. Porwit-MacDonald A; Björklund E; Lucio P; van Lochem EG; Mazur J; Parreira A; van den Beemd MW; et al. "BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL).". (2000): http://europepmc.org/abstract/med/10803512.
    10.1038/sj.leu.2401741
  24. San Miguel JF; Ciudad J; Vidriales MB; Orfao A; Lucio P; Porwit-MacDonald A; Gaipa G; van Wering E; van Dongen JJ. "Immunophenotypical detection of minimal residual disease in acute leukemia.". (1999): http://europepmc.org/abstract/med/10633847.
    10.1016/s1040-8428(99)00032-3
  25. Orfao A; Schmitz G; Brando B; Ruiz-Arguelles A; Basso G; Braylan R; Rothe G; et al. "Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions.". (1999): http://europepmc.org/abstract/med/10508115.
  26. Lúcio P; Parreira A; Orfao A. "CD123hi dendritic cell lymphoma: an unusual case of non-Hodgkin lymphoma.". (1999): http://europepmc.org/abstract/med/10507983.
    10.7326/0003-4819-131-7-199910050-00035
  27. Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; et al. "Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.". (1999): http://europepmc.org/abstract/med/10086733.
    10.1038/sj/leu/2401279
  28. Lúcio PJ; Faria MT; Pinto AM; da Silva MR; Correia Júnior ME; da Costa RJ; Parreira AB; et al. "Expression of adhesion molecules in chronic B-cell lymphoproliferative disorders.". Haematologica 83 2 (1998): 104-111. http://europepmc.org/abstract/med/9549920.
  29. Passos-Coelho JL; Machado MA; Lúcio P; Leal-Da-Costa F; Silva MR; Parreira A. "Large-volume leukaphereses may be more efficient than standard-volume leukaphereses for collection of peripheral blood progenitor cells.". (1997): http://europepmc.org/abstract/med/9368183.
  30. Abecasis MM; Machado AM; Boavida G; Silva MG; Lúcio P; Ambrósio A; Jorge ML. "Haploidentical cord blood transplant contaminated with maternal T cells in a patient with advanced leukaemia.". (1996): http://europepmc.org/abstract/med/8733718.